Literature DB >> 8429827

Binding of the cocaine analog 2 beta-carbomethoxy-3 beta-(4-[125I]iodophenyl)tropane to serotonin and dopamine transporters: different ionic requirements for substrate and 2 beta-carbomethoxy-3 beta-(4-[125I]iodophenyl)tropane binding.

S C Wall1, R B Innis, G Rudnick.   

Abstract

The iodinated cocaine analog 2 beta-carbomethoxy-3 beta-(4- [125I]iodophenyl)tropane (beta-[125I]CIT) binds with high affinity to the platelet plasma membrane serotonin transporter, as previously reported for dopamine transporters from rat brain [Eur. J. Pharmacol. 194:133-134 (1991)]. Unlabeled beta-CIT also inhibits serotonin transport by platelet membrane vesicles. In both rat striatal membranes and platelet plasma membranes, beta-[125I]CIT binding was found to be pH dependent, with a pKa of 6.4-6.9, and did not require the presence of Cl-. Na+ dramatically stimulated beta-[125I]CIT binding to both serotonin and dopamine transporters, although a small fraction of beta-[125I]CIT binding to the serotonin transporter was observed in the absence of Na+. The substrates serotonin and dopamine competed with beta-[125I]CIT for binding to their respective transporters. However, substrate affinity was enhanced by Cl-, whereas beta-[125I]CIT binding affinity was not. [3H]Imipramine binding to the platelet serotonin transporter and [3H]GBR-12935 binding to the dopamine transporter were not inhibited by decreasing the pH from 8 to 6.5. Likewise, the ability of serotonin to compete with [3H]imipramine binding and that of dopamine to inhibit [3H]GBR-12935 binding were equal at pH 6.5 or 8. Thus, beta-[125I]CIT binding to biogenic amine transporters is distinct from serotonin or dopamine binding by virtue of its inhibition by H+ and its insensitivity to Cl-.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8429827

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  7 in total

1.  Transmembrane domain I contributes to the permeation pathway for serotonin and ions in the serotonin transporter.

Authors:  E L Barker; K R Moore; F Rakhshan; R D Blakely
Journal:  J Neurosci       Date:  1999-06-15       Impact factor: 6.167

2.  At diabetes-like concentration, glucose down-regulates the placental serotonin transport system in a cell-cycle-dependent manner.

Authors:  R Unal; B A Ahmed; B C Jeffus; J T Harney; C S Lyle; Y-K Wu; T C Chambers; E A Reece; F Kilic
Journal:  J Neurochem       Date:  2007-03-12       Impact factor: 5.372

3.  Initial experience with single-photon emission tomography using iodine-123-labelled 2 beta-carbomethoxy-3 beta-(4-iodophenyl) tropane in human brain.

Authors:  J T Kuikka; K A Bergström; E Vanninen; V Laulumaa; P Hartikainen; E Länsimies
Journal:  Eur J Nucl Med       Date:  1993-09

4.  Computational and biochemical docking of the irreversible cocaine analog RTI 82 directly demonstrates ligand positioning in the dopamine transporter central substrate-binding site.

Authors:  Rejwi Acharya Dahal; Akula Bala Pramod; Babita Sharma; Danielle Krout; James D Foster; Joo Hwan Cha; Jianjing Cao; Amy Hauck Newman; John R Lever; Roxanne A Vaughan; L Keith Henry
Journal:  J Biol Chem       Date:  2014-08-31       Impact factor: 5.157

Review 5.  PE2I: a radiopharmaceutical for in vivo exploration of the dopamine transporter.

Authors:  Patrick Emond; Denis Guilloteau; Sylvie Chalon
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

6.  Fluoxetine (Prozac) binding to serotonin transporter is modulated by chloride and conformational changes.

Authors:  Sotiria Tavoulari; Lucy R Forrest; Gary Rudnick
Journal:  J Neurosci       Date:  2009-07-29       Impact factor: 6.167

7.  The mechanistic basis for noncompetitive ibogaine inhibition of serotonin and dopamine transporters.

Authors:  Simon Bulling; Klaus Schicker; Yuan-Wei Zhang; Thomas Steinkellner; Thomas Stockner; Christian W Gruber; Stefan Boehm; Michael Freissmuth; Gary Rudnick; Harald H Sitte; Walter Sandtner
Journal:  J Biol Chem       Date:  2012-03-26       Impact factor: 5.486

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.